JP2010530238A5 - - Google Patents

Download PDF

Info

Publication number
JP2010530238A5
JP2010530238A5 JP2010512807A JP2010512807A JP2010530238A5 JP 2010530238 A5 JP2010530238 A5 JP 2010530238A5 JP 2010512807 A JP2010512807 A JP 2010512807A JP 2010512807 A JP2010512807 A JP 2010512807A JP 2010530238 A5 JP2010530238 A5 JP 2010530238A5
Authority
JP
Japan
Prior art keywords
seq
thrombin
amino acid
acid sequence
exosite
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010512807A
Other languages
English (en)
Japanese (ja)
Other versions
JP5699393B2 (ja
JP2010530238A (ja
Filing date
Publication date
Priority claimed from GBGB0711779.9A external-priority patent/GB0711779D0/en
Application filed filed Critical
Publication of JP2010530238A publication Critical patent/JP2010530238A/ja
Publication of JP2010530238A5 publication Critical patent/JP2010530238A5/ja
Application granted granted Critical
Publication of JP5699393B2 publication Critical patent/JP5699393B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010512807A 2007-06-18 2008-06-18 トロンビンインヒビター Expired - Fee Related JP5699393B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0711779.9A GB0711779D0 (en) 2007-06-18 2007-06-18 Thrombin inhibitor
GB0711779.9 2007-06-18
PCT/IB2008/002109 WO2008155658A2 (en) 2007-06-18 2008-06-18 Thrombin inhibitor

Publications (3)

Publication Number Publication Date
JP2010530238A JP2010530238A (ja) 2010-09-09
JP2010530238A5 true JP2010530238A5 (https=) 2011-08-04
JP5699393B2 JP5699393B2 (ja) 2015-04-08

Family

ID=38332312

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010512807A Expired - Fee Related JP5699393B2 (ja) 2007-06-18 2008-06-18 トロンビンインヒビター

Country Status (8)

Country Link
US (1) US9217027B2 (https=)
EP (1) EP2185185B1 (https=)
JP (1) JP5699393B2 (https=)
CN (1) CN102026652B (https=)
AU (1) AU2008264890A1 (https=)
CA (1) CA2691243A1 (https=)
GB (1) GB0711779D0 (https=)
WO (1) WO2008155658A2 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1737889E (pt) 2004-10-19 2010-12-13 Lonza Ag Método para síntese de péptidos em fase sólida
GB0711779D0 (en) 2007-06-18 2007-07-25 Univ Singapore Thrombin inhibitor
GB0907698D0 (en) * 2009-05-05 2009-06-10 Univ Singapore Method of modifying serine protease inhibitors
EP2645932B1 (en) * 2010-12-02 2016-03-02 Becton, Dickinson and Company Blood collection devices containing blood stabilization agent
US9518128B2 (en) 2011-12-14 2016-12-13 Janssen Pharmaceuticals, Inc. Thrombin-binding antibody molecules
GB201121513D0 (en) 2011-12-14 2012-01-25 Cambridge Entpr Ltd Thrombin-binding antibody molecules and uses thereof
RU2015136025A (ru) * 2013-02-01 2017-03-06 Бектон, Дикинсон энд Кампани Устройства для сбора крови, содержащие добавки, ингибирующие контактный путь свертывания крови
GB201310948D0 (en) * 2013-06-19 2013-07-31 Cambridge Entpr Ltd Screening methods
GB201406863D0 (en) * 2014-04-16 2014-05-28 Univ Leeds Compositions comprising variegin
ES2786373T3 (es) 2014-06-10 2020-10-09 Biomatrica Inc Estabilización de trombocitos a temperaturas ambiente
JP6813510B2 (ja) * 2015-06-18 2021-01-13 ナショナル ユニヴァーシティー オブ シンガポール 新規トロンビン阻害物質
KR20250047404A (ko) 2015-12-08 2025-04-03 바이오매트리카 인코포레이티드 적혈구 침강 속도의 감소
CN110139871A (zh) * 2016-12-16 2019-08-16 悉尼大学 用于治疗中风和相关凝血障碍的凝血酶抑制剂
BR102017005783A2 (pt) 2017-03-21 2018-10-02 Fund Butantan processo de obtenção de esculptina e seus fragmentos, esculptina recombinante e seus usos
WO2019030706A1 (en) 2017-08-10 2019-02-14 Janssen Pharmaceutica Nv ANTI-THROMBIN ANTIBODY MOLECULES AND METHODS OF USE IN ORTHOPEDIC SURGERY
WO2019035055A1 (en) 2017-08-16 2019-02-21 Janssen Pharmaceutica Nv ANTI-THROMBIN ANTIBODY MOLECULES AND METHODS OF USE WITH PLATELET ANTI-AGGREGATE AGENTS
US12073926B2 (en) * 2020-09-21 2024-08-27 Instrumentation Laboratory Company Detecting and monitoring oral anticoagulants or intravenous direct thrombin inhibitors in a blood sample

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1341032C (en) * 1987-01-23 2000-06-20 John L. Krstenansky Anticoagulant peptides
US5196404B1 (en) 1989-08-18 1996-09-10 Biogen Inc Inhibitors of thrombin
US6060451A (en) 1990-06-15 2000-05-09 The National Research Council Of Canada Thrombin inhibitors based on the amino acid sequence of hirudin
CA2175388A1 (en) 1993-10-25 1995-05-04 Yasuo Konishi Bivalent thrombin inhibitors
AU3479495A (en) 1994-09-30 1996-04-26 Ppl Therapeutics (Scotland) Ltd Alpha-1-antitrypsin and antithrombine-iii variants
GB9506212D0 (en) 1995-03-27 1995-05-17 Iaf Biochem Int Bifunctional thrombin inhibitors bearing highly truncated fibrinogen recognition exosite binding component
GB9613718D0 (en) 1996-06-29 1996-08-28 Thrombosis Res Inst Thrombin inhibitors
US5985833A (en) 1996-09-17 1999-11-16 Wisconsin Alumni Research Foundation Thrombin inhibitor
GB0209249D0 (en) * 2002-04-23 2002-06-05 Evolutec Ltd Anticoagulants
EP1597279A1 (en) 2003-02-27 2005-11-23 National Research Council Of Canada Peptide inhibitors of thrombin as potent anticoagulants
GB0711779D0 (en) 2007-06-18 2007-07-25 Univ Singapore Thrombin inhibitor

Similar Documents

Publication Publication Date Title
JP2010530238A5 (https=)
RU2731507C1 (ru) Gla домены в качестве нацеливающих агентов
US20230116704A1 (en) Antisense oligomers for treatment of conditions and diseases
CN109106722B (zh) 适体在自体免疫疾病的疗法和/或诊断中的用途
JP2019500346A (ja) 腎臓病の処置のための組成物と方法
JP2012512389A5 (https=)
KR20240038967A (ko) Cug 반복을 표적화하기 위한 안티센스 화합물 및 방법
JP6198277B2 (ja) 血液凝固促進に使用するための化合物
TW201103983A (en) Aptamer against chymase and use thereof
Gonzalez et al. Regulated intramembrane proteolysis of ACE2: a potential mechanism contributing to COVID-19 pathogenesis?
JP2024056926A (ja) 第Xa因子阻害剤に対する解毒剤
US20080118933A1 (en) Methods of screening for inhibitors of antiplasmin cleaving enzyme
WO2019167048A1 (en) Extracorporeal device and matrix for removing fibrinolytic proteins from biological fluids, methods and uses thereof
CN104450727A (zh) X-连锁低磷酸盐血症性佝偻病的致病基因及其编码蛋白质和应用
JP2004201692A5 (https=)
JP2016520570A (ja) A型インフルエンザウイルス感染の治療又は予防に使用するためのpar−4アンタゴニスト
EP3241904A1 (en) Factor xia-specific aptamers
RU2009117253A (ru) Средство для лечения и/или улучшения состояния при диссеминированном внутрисосудистом свертывании
JP2011078414A (ja) ヒトカテプシンgのためのdnaに基づくアプタマー
EP2038653A2 (en) Substrates and inhibitors of antiplasmin cleaving enzyme and methods of use
US20080057491A1 (en) Substrates and inhibitors of antiplasmin cleaving enzyme and methods of use
JP4727591B2 (ja) プロテアーゼ阻害活性を有する新規ポリペプチド
WO2019107532A1 (ja) キマーゼに対するアプタマー及びその使用
Zhang et al. Six-month clinical observation on safety and efficacy of a full-length recombinant factor VIII for on-demand treatment of Chinese patients with haemophilia A.
Benlier et al. Human Genetic Polymorphisms Associated with Susceptibility to COVID-19 Infection and Response